Association of SLC polymorphism with the chemotherapeutic regimen and overall survival
The lung carcinoma patients in the study were administered platinum-based chemotherapy along with paclitaxel, docetaxel, pemetrexed, and irinotecan. So, we chose to investigate the modifying effects of the SLC  polymorphism and its relationship to chemotherapy, and overall patient survival, as shown inSupplementary Table 2. Chemotherapy was divided into four regimens, each given to different patient groups. All lung malignancy patients received platinum-based therapy (carboplatin/cisplatin) and a second-line chemotherapy treatment such as docetaxel, pemetrexed, paclitaxel, or irinotecan. For SLCO1B3 A1683-5676G polymorphism, our results showed that patients who were given carboplatin/cisplatin along with the docetaxel and carrying heterozygous alleles (AG ) showed inferior survival outcomes as compared to the patients having wild type genotype (AA ) (MST=2.9 months versus 9.6 months, Log-Rank p=0.006, HR=14.01 ). Upon adjusting with multivariate factors such as age, gender, smoking, stage, histology, and performance status, we observed a high hazard or death ratio in the patients having heterozygous genotype (AG ) as compared to the subjects harboring wild type genotype (AA) (HR=3.84, 95% CI=1.16-12.72; p=0.02 , Figure 5 ) as shown in Supplementary Table 2 .
In the case of lung cancer subjects receiving carboplatin/cisplatin along with irinotecan, paclitaxel, or pemetrexed, no substantial correlation was seen between overall survival and SLC19A1, SLCO1B1, and SLC19A1 polymorphism Supplementary Table 2 .